Home › NCT07187180

Evaluating the Clinical Efficacy of Thulio vs. Holmium Laser Enucleation of the Prostate

Who can join

Ages 18 and older · Men · Healthy volunteers welcome

Inclusion Criteria:

* Understand and voluntarily sign an informed consent form.
* Patients must be males with a prostate, at least 18 years of age
* No prior prostate surgery

Exclusion Criteria:

* Unable/refuse to provide informed consent
* Prior prostate surgery
* Bladder stones that requiring lasering (small stone that can be removed whole is ok)
* Unable to hold anticoagulants or antiplatelets per standard protocols for surgery and up to 1 week postop.

About the study

Many consider laser enucleation of the prostate the new 'gold standard' for the surgical treatment of benign prostatic hyperplasia (BPH) due to its excellent outcomes, high success rates, and long-term efficacy. Holmium laser enucleation of the prostate (HoLEP) was the earliest form of prostate enucleation and is recommended by the American Urological Association (AUA), along with thulium laser enucleation of the prostate (ThuLEP), as size-independent techniques for the management of BPH with fewer complications than transurethral resection of the prostate (TURP). Further development of laser technology has additionally led to enucleation using pulsed-modulated (e.g. "Virtual Basket™" mode or MOSES™ mode) holmium lasers as well as the thulium fiber laser.

What is being tested

• holmium laser (device)
• pulsed thulium laser (device)

Sponsor: Smita De · Participants: 50 · Started: Jun 2, 2025

Contact the study team

• Iva Markovic · Phone: 216-636-9694
• Smita De, MD, PHD · Phone: 216-445-4818

Official record on ClinicalTrials.gov — NCT07187180

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.